3 recruiting. .
Follow IBD-unclassified (IBD-U): new trials by email Literature Review of IBD-unclassified (IBD-U) trials Research Report on IBD-unclassified (IBD-U)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) Guselkumab (Tremfya) - Inflammatory Bowel Disease (IBD), Crohn Disease (CD) | Recruiting | TIDHI Innovation Inc. | 200 | 2026-01-29 | 2026-08-31 | |
| Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease Ulcerative Colitis (UC), IBD-unclassified (IBD-U) | Recruiting | Medical University Innsbruck | 120 | 2025-02-17 | 2025-05-01 | |
| Family Members at INcreased-risk for Developing Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) | Recruiting | Massachusetts General Hospital | 50 | 2024-12-18 | 2026-10-07 |
Colitis, Ulcerative (3) · Crohn Disease (2) · Inflammatory Bowel Diseases (2)
Colitis (3) · Colonic Diseases (3) · Digestive System Diseases (3) · Gastroenteritis (3) · Gastrointestinal Diseases (3) · Intestinal Diseases (3) · Inflammatory Bowel Diseases (1)
guselkumab (1)
Massachusetts General Hospital (1) · Medical University Innsbruck (1) · TIDHI Innovation Inc. (1)
Austria (1) · Canada (1) · United States (1)
Emily W Lopes, MD, MPH (1) · Laura E. Targownik, MD, MSHS, FRCPC (1) · Mark Silverberg, MD, PhD, FRCPC (1)